Supraoptimal peptide major histocompatibility complex causes a decrease in Bcl-2 levels and allows tumor necrosis factor α receptor II-mediated apoptosis of cytotoxic T lymphocytes

被引:87
作者
Alexander-Miller, MA
Derby, MA
Sarin, A
Henkart, PA
Berzofsky, JA
机构
[1] NCI, Metab Branch, Mol Immunogenet & Vaccine Res Sect, NIH, Bethesda, MD 20892 USA
[2] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA
关键词
T lymphocytes; cytotoxic; apoptosis; protooncogene; proteins c-bel-2; tumor necrosis factor;
D O I
10.1084/jem.188.8.1391
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cytotoxic T lymphocytes (CTLs) are primary mediators of viral clearance, but high viral burden can result in deletion of antigen-specific CTLs. We previously reported a potential mechanism for this deletion: tumor necrosis factor (TNF)-alpha-mediated apoptosis resulting from stimulation with supraoptimal peptide-major histocompatibility complex. Here, we show that although death is mediated by TNF-alpha and its receptor (TNF-RII), surprisingly neither the antigen dose dependence of TNF-alpha. production nor that of TNF-RII expression can account for the dose dependence of apoptosis. Rather, a previously unrecognized effect of supraoptimal antigen in markedly decreasing levels of the antiapoptotic protein Bcl-2 was discovered and is likely to account for the gain in susceptibility or competence to sustain the death signal through TNF-RII. This decrease requires a signal through the TCR, not just through TNF-RII. Although death mediated by TNF-RII is not as widely studied as that mediated by TNF-RI, we show here that it is also dependent on proteolytic cleavage by caspases and triggered by a brief initial encounter with antigen. These results suggest that determinant density can regulate the immune response by altering the sensitivity of CTLs to the apoptotic effects of TNF-alpha by decreasing Bcl-2 levels.
引用
收藏
页码:1391 / 1399
页数:9
相关论文
共 40 条
  • [1] Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL
    AlexanderMiller, MA
    Leggatt, GR
    Sarin, A
    Berzofsky, JA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 184 (02) : 485 - 492
  • [2] Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy
    AlexanderMiller, MA
    Leggatt, GR
    Berzofsky, JA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (09) : 4102 - 4107
  • [3] BOEHME SA, 1995, J IMMUNOL, V155, P1703
  • [4] QUANTITATIVE-ANALYSIS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOTOXIC LYMPHOCYTE-T (CTL) RESPONSE AT DIFFERENT STAGES OF HIV-1 INFECTION - DIFFERENTIAL CTL RESPONSES TO HIV-1 AND EPSTEIN-BARR-VIRUS IN LATE DISEASE
    CARMICHAEL, A
    JIN, X
    SISSONS, P
    BORYSIEWICZ, L
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 177 (02) : 249 - 256
  • [5] CHEN M, 1995, CANCER RES, V55, P991
  • [6] Chinnaiyan AM, 1996, CURR BIOL, V6, P555
  • [7] T-CELL DELETION IN HIGH ANTIGEN DOSE THERAPY OF AUTOIMMUNE ENCEPHALOMYELITIS
    CRITCHFIELD, JM
    RACKE, MK
    ZUNIGAPFLUCKER, JC
    CANNELLA, B
    RAINE, CS
    GOVERMAN, J
    LENARDO, MJ
    [J]. SCIENCE, 1994, 263 (5150) : 1139 - 1143
  • [8] PARAMETERS CONTROLLING THE PROGRAMMED DEATH OF MATURE MOUSE T-LYMPHOCYTES IN HIGH-DOSE SUPPRESSION
    CRITCHFIELD, JM
    ZUNIGAPFLUCKER, JC
    LENARDO, MJ
    [J]. CELLULAR IMMUNOLOGY, 1995, 160 (01) : 71 - 78
  • [9] Gallimore A, 1998, J EXP MED, V187, P1647
  • [10] THE TRANSMEMBRANE FORM OF TUMOR-NECROSIS-FACTOR IS THE PRIME ACTIVATING LIGAND OF THE 80 KDA TUMOR-NECROSIS-FACTOR RECEPTOR
    GRELL, M
    DOUNI, E
    WAJANT, H
    LOHDEN, M
    CLAUSS, M
    MAXEINER, B
    GEORGOPOULOS, S
    LESSLAUER, W
    KOLLIAS, G
    PFIZENMAIER, K
    SCHEURICH, P
    [J]. CELL, 1995, 83 (05) : 793 - 802